Opendata, web and dolomites

Sencell16

Lifecare’s Sencell sensor is an implantable micro-sensor for subcutaneous location, long time, continuous, wireless, real time monitoring of interstitial glucose for diabetes management.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Sencell16 project word cloud

Explore the words cloud of the Sencell16 project. It provides you a very rough idea of what is the project "Sencell16" about.

concanavalin    osmotic    subcutaneous    unlike    translates    alternatives    proprietary    noninvasively    doses    reducing    cavity    cona    protruding    significantly    core    located    automatically    interstitial    contains    communication    transmitter    induce    covered    space    semi    places    sites    membrane    intended    reading    material    cell    hyperglycemia    biocompatible    independently    inner    signal    transducer    wires    body    arm    sensor    insertion    influence    signals    wrist    mobile    skin    monitoring    utilizes    accurate    longer    sugar    blood    sensitivity    sensors    autonomously    operation    designed    prompting    warning    enzymatic    physical    inside    sencell    device    fluid    generate    substances    user    medical    function    enclosed    miniaturized    final    glucose    relayed    time    patented    pressure    battery    hypoglycemia    entire    subcutaneously    dextran    suitable    improves    permeable    implanted    insulin    encased   

Project "Sencell16" data sheet

The following table provides information about the project.

Coordinator
LIFECARE AS 

Organization address
address: OVRE KRAKENES 17
city: BERGEN
postcode: 5152
website: www.lifecare.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.lifecare.no
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIFECARE AS NO (BERGEN) coordinator 50˙000.00

Map

 Project objective

The SENCELL Glucose Monitoring System includes an osmotic pressure sensor, transmitter and mobile medical application. The miniaturized sensor is designed to be implanted into the subcutaneous space of arm wrist or other suitable body sites and requires no battery or wires for the sensor operation and for communication with the transmitter. After insertion, the sensor is designed to function noninvasively, automatically, and continuously for a long term duration that is comparable or longer than existing product alternatives.

The miniaturized SENCELL is designed to continuously measure glucose in the interstitial fluid for a long term duration that is comparable or longer than existing product alternatives. Unlike currently used glucose sensors, the Sencell is intended to be implanted subcutaneously on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin.

Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used for determination of insulin doses and to generate warning signals in case of hypoglycemia or hyperglycemia development.

The inner core of the device is the unique and proprietary osmotic patented pressure cell, which is covered on one side by a semi-permeable membrane. The membrane is enclosed inside the top of a cavity where the pressure transducer is also located. The cavity contains Concanavalin A and Dextran.

The use of ConA/Dextran as enzymatic component significantly improves the sensitivity to changes in the blood sugar level while reducing the influence from other substances in the blood. In the final product, the measurement is then relayed to the transmitter. The entire measurement is designed to be done autonomously and independently without any prompting by the user. However, the user can induce a measurement at any time

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENCELL16" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENCELL16" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More